STOCK TITAN

Royalty Pharma plc (RPRX) 10-K Filings

RPRX NASDAQ

Here are the 10-K annual reports from Royalty Pharma plc (RPRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow RPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPRX filings page.

Rhea-AI Summary

Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, funding innovation by purchasing interests in drug sales from academic, biotech and large pharma partners. Its portfolio spans royalties on more than 35 marketed therapies and 20 development-stage product candidates.

In 2025, the company generated $3.3 billion of Portfolio Receipts, mainly cash flows from existing royalty investments, and announced transactions with total potential value of $4.7 billion, deploying $2.6 billion of cash into new royalties and related assets. The portfolio includes 16 therapies each with over $1 billion in 2025 end‑market sales, providing diversified exposure across rare disease, oncology, neuroscience, immunology and other areas.

Royalty Pharma emphasizes long-duration cash flows, selective capital deployment and a flexible structuring toolkit, including third‑party royalties, synthetic royalties and other funding arrangements. Key risks center on product sales performance, development‑stage failures, competition for royalties, leverage, and regulatory and market uncertainties in the global biopharmaceutical sector.